CXCR4 and cancer: Combined therapeutic targeting of CXCR4 and PD-1 appears promising and is under phase 1 and 2 clinical trial evaluation for various cancers (NCT04058145, NCT03628859, NCT04177810, NCT02826486, NCT03168139, and NCT04177810) [11–13].